# DPTX3186 in Wnt Pathway Activated Solid Tumors

> **NCT07312903** · PHASE1 · RECRUITING · sponsor: **Dewpoint Therapeutics** · enrollment: 40 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** DPTX3186

## Key facts

- **NCT ID:** NCT07312903
- **Lead sponsor:** Dewpoint Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07312903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07312903, "DPTX3186 in Wnt Pathway Activated Solid Tumors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07312903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*